Kisunla (lecanemab) represents a shift in how we approach Alzheimer’s disease management by offering a treatment option designed to work beyond an initial therapy phase. Unlike traditional medications that address symptoms briefly, Kisunla functions as a disease-modifying therapy targeting amyloid-beta buildup in the brain—the hallmark pathology of Alzheimer’s. Extended therapy with this medication means continuing treatment over an longer timeframe to provide sustained cognitive benefit, rather than stopping after completing an initial protocol. For someone like Margaret, a 68-year-old diagnosed with mild cognitive impairment, this extended approach allows for continued slowing of cognitive decline rather than watching disease progression resume after treatment ends.
The concept of extended therapy post-treatment reflects an important reality: Alzheimer’s is a progressive disease that does not stop on its own. Once amyloid-beta pathology has begun damaging the brain, simply completing a standard course of treatment and then stopping leaves patients vulnerable to renewed decline. Extended therapy options recognize that sustained management—not punctuated treatment followed by gaps—may better preserve cognitive function over time. This approach fundamentally changes the conversation from “treating until symptoms improve” to “managing the underlying disease process over years.”.
Table of Contents
- How Does Kisunla Extended Therapy Differ From Initial Treatment?
- Clinical Considerations for Continuing Kisunla Beyond Initial Treatment
- Cognitive and Functional Outcomes in Extended Therapy
- Practical Implementation and Treatment Schedules
- Amyloid-Related Imaging Abnormalities and Safety Monitoring
- Biomarker Monitoring and Treatment Response Assessment
- Discontinuation and Transition Planning
How Does Kisunla Extended Therapy Differ From Initial Treatment?
The initial phase of Kisunla treatment typically involves an induction period with gradually increasing doses administered through infusions, allowing the body to tolerate the medication and reach therapeutic levels. Extended therapy shifts from this build-up approach to a maintenance strategy designed to maintain steady drug levels and continued target engagement. Rather than stopping after induction, extended therapy continues at a consistent maintenance dose, providing ongoing exposure to the medication’s disease-modifying effects. This distinction matters because disease progression does not pause simply because treatment has ended.
Amyloid-beta continues to accumulate and damage neuronal connections, particularly in patients with mild cognitive impairment or early dementia stages. Studies of other disease-modifying therapies have shown that withdrawing treatment often results in a return toward baseline cognitive decline patterns—a reminder that the disease itself remains active. Extended therapy aims to prevent this rebound effect by maintaining continuous therapeutic pressure against amyloid-beta buildup. The practical difference between initial and extended therapy also involves monitoring intensity and adjustment protocols. Initial treatment phases often require more frequent clinical visits and infusions, while extended therapy may involve less frequent dosing schedules but sustained cognitive and biomarker monitoring to ensure ongoing benefit and tolerability.
Clinical Considerations for Continuing Kisunla Beyond Initial Treatment
One critical limitation of extended therapy is the requirement for long-term clinical monitoring and commitment. Patients continuing Kisunla must have regular follow-up appointments, cognitive assessments, and potentially brain imaging (like MRI) to monitor for amyloid-related imaging abnormalities (ARIA), a side effect characterized by microhemorrhages or brain microinfarcts that can occur with anti-amyloid therapies. Some patients experience cognitive or functional decline that might warrant pausing or stopping therapy, and healthcare providers must actively assess whether continued treatment remains beneficial and safe for each individual. The decision to extend therapy also depends on how patients tolerate the initial phase. While many people tolerate Kisunla well, others may experience infusion reactions, flu-like symptoms, or develop imaging abnormalities that contraindicate continuation.
A patient who develops significant ARIA, for example, may not be a candidate for extended therapy at all—a sobering reminder that disease-modifying treatments are not universally appropriate or sustainable for everyone. The clinical team must continuously weigh the cognitive benefit against neuroimaging findings and symptom burden. Another consideration is the question of reversibility and timing. Extended therapy assumes that a disease-modifying approach is appropriate for months or years, but research continues to evolve regarding optimal treatment duration, the trajectory of benefit, and whether there are points at which continued therapy provides diminishing returns. This uncertainty means ongoing shared decision-making between patients, families, and clinicians is essential.
Cognitive and Functional Outcomes in Extended Therapy
The rationale for extending Kisunla therapy rests on the assumption that sustained reduction of amyloid-beta translates to preserved cognitive function over time. For someone maintaining stable or slowly declining cognition on extended therapy, the comparison is often with untreated patients experiencing typical Alzheimer’s decline—a visual distinction that may show slower slope of decline, though the magnitude varies among individuals. One patient might maintain relatively stable naming and memory abilities over 18 months of extended therapy, while cognitive decline resumes more steeply after treatment stops in an untreated control group. Functional outcomes—a person’s actual ability to perform daily activities—represent the ultimate measure of therapy success but are more complex than cognitive test scores. A person’s memory might show slower decline on extended therapy, yet if they still require increasing assistance with medication management, meal preparation, or financial decisions, the functional benefit remains modest.
Extended therapy may slow the rate at which someone requires more care, but it does not restore lost function or arrest the disease entirely. This distinction between slowing decline and reversing damage is critical for realistic expectations. The variability in response to extended therapy is substantial. Genetic factors, disease stage at initiation, comorbid conditions, and even baseline amyloid burden all influence how well someone responds. A 65-year-old with mild cognitive impairment and high amyloid burden may show meaningful cognitive stability on extended therapy, while an 80-year-old with advanced pathology may see minimal benefit despite continuing treatment. This heterogeneity underscores why population-level data on “average benefit” may not predict individual outcomes.
Practical Implementation and Treatment Schedules
Implementing extended Kisunla therapy requires infrastructure that many communities lack. Infusions must occur in specialized settings with trained staff, equipment for monitoring, and ability to manage potential infusion reactions. Unlike oral medications a patient takes at home, extended Kisunla therapy typically requires travel to an infusion center every few weeks—a burden for patients with cognitive decline who may struggle with transportation, scheduling, and sitting through multi-hour appointments. For rural or underserved populations, this logistical barrier may make extended therapy inaccessible regardless of clinical benefit. The treatment schedule itself involves trade-offs between convenience and therapeutic efficacy.
More frequent dosing provides more continuous drug exposure but requires more clinic visits; less frequent maintenance schedules reduce appointment burden but may result in fluctuating drug levels. Healthcare systems must balance patient capacity and preference against the clinical goal of maintaining steady amyloid suppression. Some patients accept the inconvenience of bi-weekly infusions to prioritize sustained cognitive benefit, while others discontinue after initial treatment specifically because extended appointments conflict with work, caregiving responsibilities, or personal preference for minimizing medical interventions. Insurance coverage and cost represent another substantial practical barrier. Even for patients who tolerate the medication well and show cognitive benefit, insurance denial or high out-of-pocket costs may force discontinuation. This reality means extended therapy remains inaccessible for many who could potentially benefit—a disparity shaped by payer policy rather than clinical indication.
Amyloid-Related Imaging Abnormalities and Safety Monitoring
ARIA represents the most significant safety concern limiting extended therapy continuation. These imaging abnormalities—microhemorrhages (ARIA-H) or microinfarcts (ARIA-E)—occur in a subset of patients receiving anti-amyloid monoclonal antibodies and can be associated with cognitive worsening or neurological symptoms. The presence of ARIA on MRI often prompts clinicians to pause or discontinue therapy, even if cognitive decline has stabilized otherwise. For a patient whose extended therapy plan involves years of treatment, the discovery of ARIA creates a sudden inflection point requiring difficult decision-making about continuing therapy versus stopping to prevent potential neurological harm. The challenge is that ARIA presence alone does not always predict clinical consequences.
Some patients with ARIA imaging findings remain cognitively stable, while others experience associated confusion, headache, or accelerated decline. This uncertainty means clinicians and patients face decisions without clear guidance on risk—a limitation of current safety monitoring. The requirement for serial MRI imaging to detect ARIA adds cost, logistical burden, and timing considerations that must be integrated into extended therapy planning. Risk factors for developing ARIA include older age, genetic predisposition (particularly APOE4 status), and possibly higher amyloid burden at baseline. Patients inherently at higher ARIA risk face a narrower therapeutic window: the cognitive benefit of extended therapy must substantially outweigh the imaging and potential clinical risks. Some patients in this category may be counseled against extended therapy altogether, even if initial tolerance was good.
Biomarker Monitoring and Treatment Response Assessment
Extended Kisunla therapy relies increasingly on biomarker monitoring—blood tests measuring phosphorylated tau, plasma p-tau variants, and amyloid-beta levels—to assess whether therapy is achieving its biological goal of reducing amyloid pathology. These plasma biomarkers provide a window into brain amyloid burden without requiring PET imaging, making it feasible to track whether extended therapy is maintaining target engagement over months or years. A patient showing persistently elevated amyloid-related biomarkers despite extended therapy may not be achieving expected biological effect, prompting discussion of dosing adjustments or alternative strategies.
The relationship between biomarker change and clinical outcome, however, remains incompletely understood. Some patients show marked biomarker improvement on extended therapy but minimal cognitive benefit, while others show modest biomarker changes with relatively preserved cognition. This dissociation underscores that amyloid reduction is necessary but may not be sufficient for meaningful clinical benefit—a humbling reminder of the complexity of Alzheimer’s pathology and why treating a single target does not guarantee disease-level improvement for all patients.
Discontinuation and Transition Planning
Extended therapy does not assume indefinite continuation for all patients. Some patients discontinue after reaching a defined endpoint; others stop due to intolerance, ARIA, lack of benefit, or personal preference. Planning for potential discontinuation is part of responsible extended therapy management, yet many patients and families experience surprise or distress when clinicians discuss stopping Kisunla after investing time and expectation in extended treatment.
Setting realistic expectations about treatment duration, potential stopping points, and what cognitive trajectory might look like post-discontinuation requires explicit conversation early in extended therapy, not retroactively when discontinuation becomes necessary. For patients discontinuing extended Kisunla therapy, cognitive decline often resumes at rates consistent with untreated Alzheimer’s disease—a reality that can feel like losing ground even if the patient’s absolute cognitive level remains higher than it would have been without therapy. This pattern has led some patients and families to feel “trapped” in extended therapy, fearing that stopping will precipitate decline, and consequently continuing treatment despite accumulating toxicities or decreasing benefit. Careful monitoring and honest communication about benefit-risk ratios can help patients make informed choices about when continued therapy genuinely aligns with their goals.
